What is Brenus Pharma?
Brenus Pharma is a biopharmaceutical company dedicated to pioneering first-in-class immunotherapies designed to bolster the immune system's response against various cancers, with a particular emphasis on solid tumors. The company's core innovation lies in its proprietary Stimulated Tumor Ghost Cells (SGC) technology. This advanced platform aims to overcome the inherent limitations of existing immunotherapies by effectively simulating tumor heterogeneity, thereby enhancing treatment efficacy and patient accessibility. Brenus Pharma's therapeutic approach is geared towards a broad patient population affected by cancers such as colorectal and ovarian cancers. The company also highlights a scalable and cost-efficient manufacturing process, positioning it for broader market impact. With a strong foundation of funding and a team of seasoned experts, Brenus Pharma is committed to advancing precision medicine and delivering novel therapeutic solutions in the fight against cancer.
How much funding has Brenus Pharma raised?
Brenus Pharma has raised a total of $25M across 1 funding round:
Series A
$25M
Series A (2024): $25M with participation from Crédit Agricole Centre France - Gaillard, Crédit agricole Centre-est, UI Investissement, and Angelor
Key Investors in Brenus Pharma
Crédit Agricole Centre France - Gaillard
Crédit Agricole Centre France - Gaillard operates within the insurance sector, indicating a potential interest in healthcare-related ventures and risk management within the life sciences.
Crédit agricole Centre-est
Crédit agricole Centre-est is a financial services and banking institution in France, suggesting a broad investment mandate that may include strategic capital allocation to growing industries like biotechnology.
UI Investissement
UI Investissement specializes in supporting the growth of small and medium-sized businesses across France, providing capital and strategic guidance to help companies achieve their full potential, aligning with Brenus Pharma's scaling objectives.
What's next for Brenus Pharma?
The recent major enterprise-level funding, including a significant strategic investment, positions Brenus Pharma for accelerated growth and the advancement of its pipeline. This capital will likely be instrumental in scaling its operations, expanding its clinical trial programs, and further developing its SGC technology. The company's focus on solid tumors and its innovative manufacturing approach suggest a strategic push towards commercialization and broader market penetration. Brenus Pharma's trajectory indicates a move towards later-stage development and potential market entry, leveraging this investment to solidify its position in the competitive immunotherapy landscape.
See full Brenus Pharma company page
